FDA Plans Behind-The-Counter Drugs Meeting, Mulls “Transitional” Status
This article was originally published in The Tan Sheet
Executive Summary
FDA will discuss the idea of behind-the-counter drug sales as a possible transitional stage between Rx and OTC status when it holds a forum on the topic with stakeholders
You may also be interested in...
FDA Awaits GAO Report To Guide Behind-The-Counter Policy
The Government Accountability Office's anticipated updated report on a behind-the-counter class of drugs will help shape FDA's policy, according to Connie T. Jung, senior policy advisor for Pharmacy Affairs
FDA Awaits GAO Report To Guide Behind-The-Counter Policy
The Government Accountability Office's anticipated updated report on a behind-the-counter class of drugs will help shape FDA's policy, according to Connie T. Jung, senior policy advisor for Pharmacy Affairs
FDA Awaits GAO Report To Guide Behind-The-Counter Policy
The Government Accountability Office's anticipated updated report on a behind-the-counter class of drugs will help shape FDA's policy, according to Connie T. Jung, senior policy advisor for Pharmacy Affairs